Vaxfab Enterprises FY26 profit up 523%; board meet Aug 14

Overview: results momentum meets governance scrutiny

Vaxfab Enterprises Limited has lined up a key Board of Directors meeting for Friday, August 14, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY2027). The update comes after the company reported a sharp improvement in FY26 standalone performance, alongside an auditor disclaimer on both standalone and consolidated numbers due to documentation gaps. Investors are also tracking how quarterly profitability has moved across FY26, where reported figures vary by statement type and presentation. On the market side, the stock was cited at ₹64.95 at the close of the market in one update, while another snippet referenced ₹60.75 (BSE, 05 Jun, 4:00 PM).

Board meeting on August 14: what is on the agenda

The company has issued a notice that its board will meet on August 14, 2026. The purpose, as disclosed, is to consider and approve the unaudited financial results for the quarter ended June 30, 2026. Such board meetings are routine in the reporting calendar, but they tend to matter more when a company is coming off a volatile set of quarterly prints and heightened audit attention. For investors, the Q1 FY27 numbers will be the first quarterly update after FY26 audited results were approved by the board on May 30, 2026.

Trading window closure: compliance timeline

Vaxfab also confirmed that the trading window for all designated persons was closed starting July 01, 2026. The company said this had been previously communicated in a submission dated June 29, 2026. The window closure will remain in effect until 48 hours after submission of the unaudited financial results for the quarter ended June 30, 2026. Trading window restrictions are part of insider trading compliance practices, aimed at limiting trading by insiders while unpublished price sensitive information is pending.

FY26 at a glance: standalone profit, consolidated loss

For the financial year ended March 31, 2026, Vaxfab Enterprises reported a standalone profit of ₹3.64 crore (also presented as ₹363.80 lakh). In the same period, the company’s consolidated results showed a loss of ₹4.63 crore (₹463.08 lakh). This divergence between standalone and consolidated outcomes is important for investors to note, because consolidated figures typically include subsidiaries and group-level adjustments that may not be visible in standalone reporting.

Auditor disclaimer: what was flagged

Statutory auditors Chandabhoy & Jassoobhoy issued a disclaimer of opinion on both standalone and consolidated financial results. The reason cited was inadequate record-keeping by previous management and unsecured loans without formal agreements. A disclaimer of opinion is a serious audit outcome in which the auditor is unable to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion. The disclosure did not, in the provided text, quantify the impact of the documentation issues on specific line items.

FY26 growth metrics that drove market attention

Vaxfab’s FY26 standalone performance, as cited in the supplied data, showed strong year-on-year expansion. Standalone total income was reported at ₹99.60 crore for FY26 compared with ₹59.38 crore in the previous financial year, a YoY rise of 67.7%. Net profit for FY26 stood at ₹3.64 crore versus ₹0.58 crore in FY25, reflecting a YoY increase of 523%. EBITDA was reported at ₹5.21 crore in FY26 compared with ₹0.74 crore in FY25. Earnings per share for FY26 was reported at ₹4.33.

Q4 FY26 and March 2026 quarter: multiple reported snapshots

For the quarter ended March 2026 (Q4 FY26), one performance snapshot reported total income of ₹18.37 crore and net profit of ₹3.01 crore, compared with ₹0.70 crore in the same quarter last year, indicating YoY growth of 329%. The same snapshot reported EBITDA of ₹6.98 crore and EPS of ₹3.59.

Another set of quarterly figures (presented as “Quarterly Result”) showed for Mar 2026: Net Sales of ₹8.83 crore, Other Income of ₹9.53 crore, Profit Before Tax of ₹6.97 crore, Tax of ₹3.96 crore, and Profit After Tax of ₹3.02 crore, with adjusted EPS of ₹3.59. Separately, consolidated quarterly numbers were cited as Net Sales of ₹45.99 crore in March 2026, Net Profit of ₹2.14 crore (up 168.96% from ₹0.80 crore in March 2025), and EPS of ₹0.26 in March 2026 versus ₹0.09 in March 2025.

The data set also included a headline stating quarterly earnings growth YoY of -47.03% and a statement that net profit fell -47.03% to ₹2.14 crore in Q4 2025-2026, while another line in the same context described a 166.05% QoQ jump in net profits. These differences likely reflect different bases (standalone vs consolidated, or different definitions of the comparable quarter), but the supplied text does not reconcile them into a single standardized figure.

Key numbers table: FY26 and Q4 FY26 highlights (as reported)

Stock price references and key dates

Two different price points were cited in the provided material: ₹64.95 as the close-of-market share price in one update, and ₹60.75 in another reference (BSE, 05 Jun, 4:00 PM). Without additional context, these should be read as different timestamps rather than conflicting quotes.

Why the August results matter for investors

The scheduled August 14 board meeting sets a clear near-term date for fresh financial data, particularly after a year that combined strong reported standalone growth with an audit disclaimer tied to record-keeping and unsecured loan documentation. Investors will likely compare Q1 FY27 operating performance with the uneven quarterly pattern seen across FY26, including quarters with negative operating profits in some presentations and a large contribution from other income in the Mar 2026 quarter in another presentation. The company’s disclosures on the trading window also indicate the formal compliance process around the results event.

Conclusion

Vaxfab Enterprises enters its Q1 FY27 results cycle with strong reported FY26 standalone growth metrics, but also a disclaimer of opinion from its statutory auditors on both standalone and consolidated statements. The next formal milestone is the August 14, 2026 board meeting to approve unaudited results for the quarter ended June 30, 2026, after which the trading window will reopen 48 hours following submission of results.